FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2511253226> ?p ?o ?g. }

• W2511253226 abstract "Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma and can emerge throughout the whole body. For patients with newly diagnosed RMS, prognosis for survival depends on multiple factors such as histology, tumour site, and extent of the disease. Patients with metastatic disease at diagnosis have impaired prognosis compared to those with localised disease. Appropriate staging at diagnosis therefore plays an important role in choosing the right treatment regimen for an individual patient. Fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is a functional molecular imaging technique that uses the increased glycolysis of cancer cells to visualise both structural information and metabolic activity. 18F-FDG-PET combined with computed tomography (CT) could help to accurately stage the extent of disease in patients with newly diagnosed RMS. In this review we aimed to evaluate whether 18F-FDG-PET could replace other imaging modalities for the staging of distant metastases in RMS.To determine the diagnostic accuracy of 18F-FDG-PET/CT imaging for the detection of bone, lung, and lymph node metastases in RMS patients at first diagnosis.We searched MEDLINE in PubMed (from 1966 to 23 December 2020) and Embase in Ovid (from 1980 to 23 December 2020) for potentially relevant studies. We also checked the reference lists of relevant studies and review articles; scanned conference proceedings; and contacted the authors of included studies and other experts in the field of RMS for information about any ongoing or unpublished studies. We did not impose any language restrictions.We included cross-sectional studies involving patients with newly diagnosed proven RMS, either prospective or retrospective, if they reported the diagnostic accuracy of 18F-FDG-PET/CT in diagnosing lymph node involvement or bone metastases or lung metastases or a combination of these metastases. We included studies that compared the results of the 18F-FDG-PET/CT imaging with those of histology or with evaluation by a multidisciplinary tumour board as reference standard.Two review authors independently performed study selection, data extraction, and methodological quality assessement according to Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). We analysed data for the three outcomes (nodal involvement and lung and bone metastases) separately. We used data from the 2 × 2 tables (consisting of true positives, false positives, true negatives, and false negatives) to calculate sensitivity and specificity in each study and corresponding 95% confidence intervals. We did not consider a formal meta-analysis to be relevant because of the small number of studies and substantial heterogeneity between studies.Two studies met our inclusion criteria. The diagnostic accuracy of 18F-FDG-PET/CT was reported in both studies, which included a total of 36 participants. We considered both studies to be at high risk of bias for the domain reference standard. We considered one study to be at high risk of bias for the domain index test and flow and timing. Sensitivity and specificity of 18F-FDG-PET/CT for the detection of bone metastases was 100% in both studies (95% confidence interval (CI) for sensitivity was 29% to 100% in study one and 40% to 100% in study two; 95% CI for specificity was 83% to 100% in study one and 66% to 100% in study two). The reported sensitivity of 18F-FDG-PET/CT for the detection of lung metastases was not calculated since only two participants in study two showed lung metastases, of which one was detected by 18F-FDG-PET/CT. Reported specificity was 96% in study one (95% CI 78% to 100%) and 100% (95% CI 72% to 100%) in study two. The reported sensitivity for the detection of nodal involvement was 100% (95% CI 63% to 100% in study one and 40% to 100% in study two); the reported specificity was 100% (95% CI 78% to 100%) in study one and 89% (95% CI 52% to 100%) in study two.The diagnostic accuracy of 18F-FDG-PET/CT for the detection of bone, lung, and lymph node metastases was reported in only two studies including a total of only 36 participants with newly diagnosed RMS. Because of the small number of studies (and participants), there is currently insufficient evidence to reliably determine the diagnostic accuracy of 18F-FDG-PET/CT in the detection of distant metastases. Larger series evaluating the diagnostic accuracy of 18F-FDG-PET/CT for the detection of metastases in patients with RMS are necessary." @default.
• W2511253226 created "2016-09-16" @default.
• W2511253226 creator A5006080248 @default.
• W2511253226 creator A5006518748 @default.
• W2511253226 creator A5010615884 @default.
• W2511253226 creator A5027348510 @default.
• W2511253226 creator A5028460227 @default.
• W2511253226 creator A5029704913 @default.
• W2511253226 creator A5039164901 @default.
• W2511253226 creator A5053261079 @default.
• W2511253226 creator A5063070002 @default.
• W2511253226 creator A5065228177 @default.
• W2511253226 date "2021-11-09" @default.
• W2511253226 modified "2023-09-30" @default.
• W2511253226 title "Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma" @default.
• W2511253226 cites W143755005 @default.
• W2511253226 cites W1536359632 @default.
• W2511253226 cites W1558704041 @default.
• W2511253226 cites W1844874351 @default.
• W2511253226 cites W1926287352 @default.
• W2511253226 cites W1967911585 @default.
• W2511253226 cites W1973723716 @default.
• W2511253226 cites W1974939309 @default.
• W2511253226 cites W1986038528 @default.
• W2511253226 cites W1988172747 @default.
• W2511253226 cites W1989380797 @default.
• W2511253226 cites W1991673269 @default.
• W2511253226 cites W1993515840 @default.
• W2511253226 cites W2000426190 @default.
• W2511253226 cites W2001786321 @default.
• W2511253226 cites W2007092858 @default.
• W2511253226 cites W2017887715 @default.
• W2511253226 cites W2020111485 @default.
• W2511253226 cites W2023187432 @default.
• W2511253226 cites W2033889372 @default.
• W2511253226 cites W2034903235 @default.
• W2511253226 cites W2037384834 @default.
• W2511253226 cites W2040051511 @default.
• W2511253226 cites W2043680485 @default.
• W2511253226 cites W2044759862 @default.
• W2511253226 cites W2049514035 @default.
• W2511253226 cites W2071837913 @default.
• W2511253226 cites W2075207955 @default.
• W2511253226 cites W2075660225 @default.
• W2511253226 cites W2082966879 @default.
• W2511253226 cites W2091959444 @default.
• W2511253226 cites W2100034382 @default.
• W2511253226 cites W2103690933 @default.
• W2511253226 cites W2103879617 @default.
• W2511253226 cites W2107638293 @default.
• W2511253226 cites W2109400179 @default.
• W2511253226 cites W2110366492 @default.
• W2511253226 cites W2110648476 @default.
• W2511253226 cites W2112309180 @default.
• W2511253226 cites W2112772060 @default.
• W2511253226 cites W2123081410 @default.
• W2511253226 cites W2129430773 @default.
• W2511253226 cites W2141834520 @default.
• W2511253226 cites W2143542249 @default.
• W2511253226 cites W2148937579 @default.
• W2511253226 cites W2158444237 @default.
• W2511253226 cites W2163763049 @default.
• W2511253226 cites W2166853390 @default.
• W2511253226 cites W2168601799 @default.
• W2511253226 cites W2168623057 @default.
• W2511253226 cites W2169792285 @default.
• W2511253226 cites W2320058917 @default.
• W2511253226 cites W2329398356 @default.
• W2511253226 cites W2333985596 @default.
• W2511253226 cites W2407036517 @default.
• W2511253226 cites W2412058100 @default.
• W2511253226 cites W2507363732 @default.
• W2511253226 cites W2511253226 @default.
• W2511253226 cites W2513932156 @default.
• W2511253226 cites W2593498285 @default.
• W2511253226 cites W2754189980 @default.
• W2511253226 cites W2754362426 @default.
• W2511253226 cites W2767343386 @default.
• W2511253226 cites W2800437386 @default.
• W2511253226 cites W2806271709 @default.
• W2511253226 cites W2809122047 @default.
• W2511253226 cites W2883645764 @default.
• W2511253226 cites W2980334953 @default.
• W2511253226 cites W3025200568 @default.
• W2511253226 cites W3042531189 @default.
• W2511253226 cites W3047586245 @default.
• W2511253226 cites W4229806319 @default.
• W2511253226 cites W4242270309 @default.
• W2511253226 cites W4245478907 @default.
• W2511253226 cites W4246134460 @default.
• W2511253226 cites W4252028591 @default.
• W2511253226 cites W4255658840 @default.
• W2511253226 cites W4255691981 @default.
• W2511253226 cites W4292223335 @default.
• W2511253226 cites W4298363383 @default.
• W2511253226 cites W4299652411 @default.
• W2511253226 doi "https://doi.org/10.1002/14651858.cd012325.pub2" @default.
• W2511253226 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8577863" @default.
• W2511253226 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34753195" @default.
• W2511253226 hasPublicationYear "2021" @default.

• next